Table 4.
Parameters | 5-year DFS (%) | P value | 5-year OS (%) | P value |
---|---|---|---|---|
Age | ||||
<65 | 59% | 0.149 | 71% | 0.238 |
≥ 65 | 43% | 62% | ||
Sex | ||||
Male | 56% | 0.160 | 70% | 0.302 |
Female | 44% | 62% | ||
Histology | ||||
Differentiated | 51% | 0.711 | 69% | 0.622 |
Undifferentiated | 50% | 65% | ||
White cell count | ||||
<4 (×109/L) | 43% | 0.390 | 58% | 0.323 |
4-8 (×109/L) | 51% | 72% | ||
> 8 (×109/L) | 56% | 67% | ||
cT | ||||
3 | 56% | 0.033* | 76% | 0.008* |
4 | 44% | 55% | ||
cN | ||||
Negative | 65% | 0.012* | 81% | 0.014* |
Positive | 43% | 59% | ||
Neo-adjuvant therapy | ||||
Chemotherapy alone | 36% | 0.023* | 70% | 0.128 |
Radiotherapy alone | 45% | 48% | ||
Chemo-radiotherapy | 61% | 74% | ||
TRG | ||||
Good response | 64% | 0.001* | 81% | 0.001* |
Poor response | 38% | 54% | ||
CD3+TILs | ||||
High | 59% | 0.010* | 75% | 0.019* |
Low | 40% | 56% | ||
CD8+ | ||||
High | 61% | 0.002* | 77% | 0.003* |
Low | 37% | 54% |
Statistically significant.